Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
September 20, 2023 04:30 ET
|
Alvotech
REYKJAVIK, Iceland, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT02 (adalimumab) í Bandaríkjunum
September 20, 2023 04:30 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hefði staðfest að umsókn Alvotech um markaðsleyfi fyrir AVT02 sem lögð hefur verið fram að nýju hafi verið...
AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors
September 18, 2023 06:00 ET
|
AiViva Biopharma
COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
Alvotech tekur þátt í 21. heilbrigðisráðstefnu Morgans Stanleys
September 11, 2023 05:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans Morgans Stanleys sem haldin verður í tuttugasta og fyrsta sinn í New York dagana 11.-13. september nk. Ming...
Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 11, 2023 05:00 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces its participation in the Morgan Stanley 21st...
Alvotech tilkynnir um breytingar í framkvæmdastjórn
September 05, 2023 09:30 ET
|
Alvotech
Alvotech (NASDAQ: ALVO, „félagið“) tilkynnti í dag um breytingar í framkvæmdastjórn félagsins. Faysal Kalmoua hefur verið skipaður framkvæmdastjóri rekstrar og Hafrún Friðriksdóttir lætur af störfum....
Alvotech Announces Changes to the Leadership Team
September 05, 2023 09:30 ET
|
Alvotech
Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Faysal Kalmoua has...
Alvotech birtir uppgjör fyrir fyrri helming ársins 2023 og kynnir helstu áfanga á liðnum ársfjórðung
August 30, 2023 16:15 ET
|
Alvotech
Sölutekjur fyrstu sex mánuði ársins jukust í 22,7 milljónir dollara samanborið við 3,9 milljónir dollara á sama tímabili í fyrraFjárfestar á Íslandi, auk Teva Pharmaceuticals Inc., skuldbundu sig til...
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 30, 2023 16:15 ET
|
Alvotech
Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022Investors, including Teva Pharmaceuticals, subscribed to Alvotech’s...
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
August 30, 2023 16:15 ET
|
Alvotech
Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022Investors, including Teva Pharmaceuticals, subscribed to Alvotech’s...